RecruitingPhase 1Phase 2NCT07299747

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors

Sponsor

VelaVigo Bio Inc

Enrollment

255 participants

Start Date

Dec 4, 2025

Study Type

INTERVENTIONAL

Conditions

Participants With Advanced Solid Tumor Malignancies

Summary

This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VBC103 for people with participants with advanced solid tumor malignancies. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVBC103

VBC103

Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07299747

Related Trials

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

NCT071367795 locations